Thursday - October 29, 2026

Non-Cystic Fibrosis Bronchiectasis Pipeline Landscape 2026: Late-Stage Candidates, MOA Trends, and ROA | Insmed, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici

(Albany, New York) – October 29, 2026: According to DelveInsight’s analysis, the global Non-Cystic Fibrosis Bronchiectasis pipeline comprises 15+ key companies actively developing 13+ therapeutic candidates. The assessment provides comprehensive insights into clinical trials, emerging therapies, mechanisms of action, routes … Continue reading →

Endometrial Cancer Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The Endometrial Cancer clinical trial analysis report delivers important insights into ongoing research on 55+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 29, 2026 – DelveInsight’s, “Endometrial Cancer Pipeline Insight 2026” report provides comprehensive … Continue reading →

Becker Muscular Dystrophy Pipeline 2026: Therapeutic Candidates, Clinical Trial Insights, and Companies Leading Drug Development | Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharma, Edgewise

(Albany, New York) – October 29, 2026: According to DelveInsight’s analysis, the global Becker Muscular Dystrophy pipeline comprises 8+ key companies actively developing 8+ therapeutic candidates. The assessment provides comprehensive insights into clinical trials, emerging therapies, mechanisms of action, routes … Continue reading →

Phoenix Home Remodeling named among the best bathroom remodelers in Phoenix by The Phoenix Review and Trust Analytica

Bathroom remodel in Phoenix, AZ Phoenix bathroom remodeling contractor Phoenix Home Remodeling has been named among the best bathroom remodelers in Phoenix by The Phoenix Review and Trust Analytica, recognizing its work for Phoenix-area homeowners. PHOENIX, Arizona – October 29, … Continue reading →

Familial Adenomatous Polyposis Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The Familial Adenomatous Polyposis market analysis report delivers important insights into ongoing research on pipeline Familial Adenomatous Polyposis drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 29, 2026, DelveInsight’s “Familial Adenomatous Polyposis Market Insights, Epidemiology and … Continue reading →

Pemphigus Vulgaris Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The Pemphigus Vulgaris market analysis report delivers important insights into ongoing research on pipeline Pemphigus Vulgaris drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 29, 2026, DelveInsight’s “Pemphigus Vulgaris Market Insights, Epidemiology and Market Forecast – … Continue reading →

Type 2 Diabetes Pipeline Outlook 2026: Oral, Injectable, and Novel Delivery Candidates Advancing Through Clinical Trials | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk

(Albany, New York) – October 29, 2026: According to DelveInsight’s analysis, the global Type 2 Diabetes pipeline comprises 75+ key companies actively developing 80+ therapeutic candidates. The assessment provides comprehensive insights into clinical trials, emerging therapies, mechanisms of action, routes … Continue reading →